Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Investor Presentation (November 2023)
7 slides from Royalty Pharma's investor presentation, November 2023
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: R&D co-funding for TEV-'749
R&D co-funding for TEV-‘749 November 2023
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: TEV-'749 can fill a void among existing LAI treatments
TEV-‘749 can fill a void among existing LAI treatments 1 2 3 Teva’s TEV-‘749 in Phase 3 TEV-‘749 designed to LAI antipsychotics an for schizophrenia reduce the risk of PDSS attractive opportunity TEV-‘749 could offer the proven efficacy of Subcutaneous injection and polymer drug- LAI antipsychotics
Slide 5: R&D partnership accelerates development of TEV-'749
R&D partnership accelerates development of TEV-‘749 • R&D funding partnership with Teva on TEV-‘749 ▪ $100m R&D funding with $25m option for additional funding Royalty interest subject to mutual agreement on TEV-‘749 ▪ Entitled to low- to mid-single digit royalty on worldwide sales ▪ R&D funding pay
Slide 6: TEV-'749 offers a potentially compelling profile
TEV-‘749 offers a potentially compelling profile Zyprexa Relprevv(1) TEV-‘749 (Lilly’s LAI olanzapine) (Teva’s LAI olanzapine) Status Approved Phase 3 development (data H2 2024) Dosing frequency Every 2 or 4 weeks Once monthly Administration Intramuscular injection Subcutaneous injection Injection 1
Slide 7: LAI antipsychotics an attractive market opportunity
LAI antipsychotics an attractive market opportunity ~$4bn U.S. LAI market growing rapidly(1) ($ in millions) • Significant opportunity for conversion of treatment with oral olanzapine to TEV-‘749 if approved with favorable safety profile +16% CAGR • LAI antipsychotics are a ~$4bn U.S. market and gro
Royalty Pharma — Investor Presentation (November 2023) on 6ix